Status:
RECRUITING
New Onset of Arrhythmia After Patent Foramen Ovale (PFO) Closure
Lead Sponsor:
Na Homolce Hospital
Conditions:
Cardiovascular Diseases
Eligibility:
All Genders
18+ years
Brief Summary
Embolic stroke of undetermined source (ESUS) accounts for approximately 25% of all ischemic strokes, with patent foramen ovale (PFO) considered a major mechanism behind ESUS. When specific anatomic cr...
Eligibility Criteria
Inclusion
- Indication for percutaneous closure of patent foramen ovale due to stroke, confirmed through an interdisciplinary meeting between cardiologists and neurologists, in accordance with current guidelines.
- Age \> 18 years.
- Written informed consent.
Exclusion
- Patients with a known history of atrial fibrillation, atrial flutter, or atrial tachycardia.
Key Trial Info
Start Date :
January 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06983613
Start Date
January 15 2025
End Date
December 31 2028
Last Update
May 21 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Nemocnice na Homolce
Prague, Czechia, 15030
2
Nemocnice na Homolce
Prague, Czechia, 15030